

PhD positions available in biomedicine & technology



We provide an international programme that builds international networks with academia, hospitals, patients' organizations and the private sector. In Emerald we combine training and mentoring, entailing an online training platform, summer schools on the latest technologies, and peer-to-peer and mentee-mentor activities. Training focuses on biomedical research and technology, open and responsible research, innovation and knowledge transfer and professional empowerment.



The fellow will additionally enrol in the international PhD programme, benefiting from competitive salaries, a creative environment, advanced training, tailored career development and mentoring programmes, and access to high-end technologies and facilities. They will be supervised by the host Principal Investigator (PI), and co-supervised by a second PI chosen by the fellow and the host PI.

Elegibility criteria



Emerald will recruit Medical Doctors of any nationality, gender, culture, religion, sexual orientation or age to undertake a PhD in biomedical or life science research. To be eligible for an **Emerald** fellowship, **applicants must:**

- Hold a **medical degree** which allows them to enrol in doctoral programme at the hosting institution.
- Comply with the **mobility rule**, meaning that they must not have resided or carried out their main activity (work, studies, etc.) in the country of the recruiting institute for more than 12 months in the 3 years immediately before the recruitment date.
- Be in the **first four years** of their research careers and have **not been awarded a doctoral degree**.

Application deadline of 1st call: **5th December 2021**

More information & application at

www.emerald-mdphd.eu

Emerald will hire in total 24 fellows in two calls. In each call the candidates can chose from a multitude of laboratories at the seven recruiting institutions to apply to.

7 Hosting centres

- Centre for Genomic Regulation (CRG)
- Flanders Institute for Biotechnology (VIB)
- Fundação Calouste Gulbenkian - Instituto Gulbenkian de Ciência (FCG-IGC)
- Institut Curie (IC)
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
- Københavns Universitet (UCPH-BRIC)
- Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis (NKI)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101034290.